{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T10:08:33Z","timestamp":1764842913682},"reference-count":17,"publisher":"Impact Journals, LLC","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2024,8,31]]},"DOI":"10.18632\/aging.206082","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T23:32:20Z","timestamp":1724542340000},"page":"12063-12072","source":"Crossref","is-referenced-by-count":1,"title":["Mechanistic study of PD-L1 regulation of metastatic proliferation in non-small cell lung cancer through modulation of IRE1\u03b1\/XBP-1 signaling pathway in tumor-associated macrophages"],"prefix":"10.18632","volume":"16","author":[{"given":"Yi","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zezheng","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2024,8,24]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jtho.2020.10.006","article-title":"Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC.","volume":"1","author":"Garon","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12943-019-1062-7","article-title":"Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations.","volume":"1","author":"Zhang","year":"2019","journal-title":"Mol Cancer"},{"key":"3","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3390\/cancers11101419","article-title":"Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities.","volume":"1","author":"Bianco","year":"2019","journal-title":"Cancers (Basel)"},{"key":"4","doi-asserted-by":"publisher","first-page":"5138","DOI":"10.3390\/ijms20205138","article-title":"Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8T Cells in Non-Small Cell Lung Cancer.","volume":"2","author":"Chen","year":"2019","journal-title":"Int J Mol Sci"},{"key":"5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/978-3-319-53156-4_5","article-title":"Immunotherapy in NSCLC: A Promising and Revolutionary Weapon.","volume":"99","author":"Mahave","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2174\/1574886311207040289","article-title":"Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management.","volume":"1","author":"Gridelli","year":"2016","journal-title":"Curr Drug Saf"},{"key":"7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s40425-019-0733-7","article-title":"Niclosamide, an antihelmintic drug, enhances efficacy of PD-1\/PD-L1 immune checkpoint blockade in non-small cell lung cancer.","volume":"7","author":"Fu","year":"2019","journal-title":"J Immunother Cancer"},{"key":"8","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.3390\/cancers11091400","article-title":"Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization.","volume":"1","author":"Cheng","year":"2019","journal-title":"Cancers (Basel)"},{"key":"9","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3389\/fonc.2019.00819","article-title":"Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report.","volume":"9","author":"F\u00edrvida","year":"2019","journal-title":"Front Oncol"},{"key":"10","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.","volume":"38","author":"Vergnenegre","year":"2019","journal-title":"N Engl J Med"},{"key":"11","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.","volume":"37","author":"Hotta","year":"2016","journal-title":"N Engl J Med"},{"key":"12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ctrv.2017.10.002","article-title":"PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.","volume":"6","author":"Stahel","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"13","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1080\/17512433.2017.1356717","article-title":"Atezolizumab for the treatment of non-small cell lung cancer.","volume":"1","author":"Rudin","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"14","doi-asserted-by":"publisher","first-page":"4325874","DOI":"10.1155\/2018\/4325874","article-title":"Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.","volume":"201","author":"Hung","year":"2018","journal-title":"J Immunol Res"},{"key":"15","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.molcel.2020.05.034","article-title":"Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy.","volume":"7","author":"Rathmell","year":"2020","journal-title":"Mol Cell"},{"key":"16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/2326-6066.CIR-16-0391","article-title":"Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.","volume":"5","author":"Schreiber","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/s1001-9294(13)60040-1","article-title":"Relationship between programmed death-ligand 1 and clinicopathological characteristics in non-small cell lung cancer patients.","volume":"2","author":"Qu","year":"2013","journal-title":"Chin Med Sci J"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.206082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T03:52:24Z","timestamp":1725594744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.206082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,24]]},"references-count":17,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,8,31]]}},"alternative-id":["206082","39189933"],"URL":"https:\/\/doi.org\/10.18632\/aging.206082","relation":{},"ISSN":["1945-4589"],"issn-type":[{"type":"electronic","value":"1945-4589"}],"subject":[],"published":{"date-parts":[[2024,8,24]]}}}